ArticlePloS one2025
The global burden of Klebsiella pneumoniae-associated lower respiratory infection in 204 countries and territories, 1990-2021: Findings from the global burden of disease study 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Safety and Immunogenicity of a Klebsiella pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study.The Journal of infectious diseases · 2026Trial
- Global, regional and national burden of chronic obstructive pulmonary disease and lower respiratory infection attributable to household air pollution and secondhand smoke from 1990 to 2021: an analysis of the Global Burden of Disease Study (GBD 2021).Journal of thoracic disease · 2026Article
- Prevalence, antimicrobial resistance, and associated factors of critical superbugs Klebsiella pneumoniae and Acinetobacter species among hospitalized patients in Northwest Ethiopia.BMC microbiology · 2026Article
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Klebsiella pneumoniae in humans, animals and the environment in Northwest Amhara, Ethiopia.Scientific reports · 2026Article
- A Rapid and Sensitive LAMP Assay for the Detection ofFoods (Basel, Switzerland) · 2026Article
- Carbapenem-resistantbioRxiv : the preprint server for biology · 2026Article
- Prevalence and Antimicrobial Resistance ofInfection and drug resistance · 2026Article
- Machine learning-assisted prognostic model for mortality in ICU patients with culture-confirmedFrontiers in cellular and infection microbiology · 2026Article
- Global Trends and Attributable Risk Factors in the Disease Burden of Lower Respiratory Infections.Tropical medicine and infectious disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the global epidemiological burden of lower respiratory infections (LRI) attributable to Klebsiella pneumoniae from 1990-2021, using data from the Global Burden of Disease Study (GBD) 2021. The findings reveal that globally, disability-adjusted life years (DALYs) from Klebsiella pneumoniae-associated LRI decreased from 16,701,044 (95% UI: 14,220,055-19,183,469) in 1990-6,935,440 (95% UI: 5,953,328-8,007,786) in 2021, while deaths declined from 239,367 (95% UI: 212,553-268,072) -175,783 (95% UI: 158,749-193,924). The age-standardized DALYs rate dropped from 313.1 (95% UI: 266.6-359.7)-87.9 (95% UI: 75.4-101.5), and the death rate decreased from 4.5 (95% UI: 4.0-5.0)-2.2 (95% UI: 2.0-2.5). In 2021, the highest rates were observed in Oceania and Sub-Saharan Africa, particularly in Central African Republic, Niger, and Zimbabwe, while the lowest rates were found in Australasia, High-income North America, Eastern Europe, and East Asia, especially in the UAE, Australia, and Qatar. Higher rates were noted among both males and females under 10 and over 65 years old. Although most regions experienced decreases in age-standardized rates(ASR) from 1990-2021, Southern Latin America exhibited an increase. Additionally, age-standardized DALYs and death rates generally declined with increasing socio-demographic index (SDI). The global burden of LRI due to Klebsiella pneumoniae significantly decreased over the study period, but lower SDI regions, children, and the elderly remain vulnerable and require targeted interventions to further reduce this burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.